Integrated Microfluidic LC-MS - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Integrated Microfluidic LC-MS
The authors describe a new microfluidic-based workflow that integrates and automates glycan cleaveage, purification, and chromatographic separation onto a microfluidic liquid chromatography–mass spectrometry chip for MS detection.


Pharmaceutical Technology
Volume 34, pp. s32-s39

β-glycosylamines versus free-reducing-end glycans

Because direct coupling of the microfluidic LC–MS chip to the TOF-MS enables detection of -glycosylamine intermediates, it is important to understand the kinetics of hydrolysis from the -glycosylamine to free-reducing end forms. By varying the glycan residence time on the PGC trapping column, it is possible to monitor the consistency of the distribution of G0, G1, and G2 during hydrolysis.


Figure 8: Kinetics of hydrolysis of β-glycosylamines to free-reducing-end forms. By varying the gradient delay time, the time the glycans were trapped on the porous graphitized chromatographic column, the glycans were allowed to hydrolyze for 0, 30, 60, and 120 min. The β-glycosylamines eluted between 2.2 and 2.4 min, and their peak intensity decreased over time. The free-reducing-end glycans eluted between 2.5 and 2.7 min, and their peak intensity increased over time. By 120 min, The β-glycosylamines were completely hydrolyzed to the free-reducing-end forms. The calculated distribution of the glycans G0, G1, and G2 was maintained.
In the time-course experiment summarized in Figure 8, the glycans remained on the trapping column for 0, 30, 60, and 120 min. The ECC's depict the decrease in abundance of the -glycosylamine forms and the corresponding conversion (increase) to the free-reducing-end forms over time. With no wait time on the trapping column, as the chip would be used in a real-time process-monitoring application, The β-glycosylamines were eluted between 2.2 and 2.4 min, and the free-reducing-end glycans were eluted between 2.5 and 2.7 min. The ECC showed that, with no wait time, the abundance counts of The β-glycosylamines were more than double those of the free-reducing-end glycans. With the microfluidic LC–MS chip approach, measuring β-glycosylamines, rather than the free-reducing-end forms, doubles the sensitivity of analysis. After 120 min, The β-glycosylamines were completely hydrolyzed to free-reducing-end forms. The relative percent of the three most abundant glycans was maintained throughout the experiment.

Analysis of intact and deglycosylated antibodies

Using a different chip configuration, it is possible to analyze deglycosylated antibody. For this analysis, the microfluidic chip was constructed of two layers rather than three: the PNGase enzyme reactor chamber and the LC–MS C8 packed chip layer. Because laser ablation of polyimide film is used, it is possible to create chips with a wide variety of features and functionality.


Figure 9: Characterization of intact and deglycosylated antibody Ab1. Figure 9 (a) shows the deconvoluted mass spectrum of the intact antibody Ab1 prior to deglycosylation. The three peaks suggest a combination of G0, G1, and G2 glycan modifications. The deconvoluted mass spectrum in Figure 9 (b) shows the partially deglycosylated antibody following a 3-s deglycosylation in the reactor chamber. Figure 9 (c) shows the single-peak mass spectrum of the completely deglycosylated antibody following a 6-s residence time in the reactor chamber. mAb is monoclonal antibody.
By varying the residence time in the reactor chamber, it is possible to determine the time required to completely deglycosylate the antibody. Figure 9 shows the results from the analysis of intact and degylcosylated antibody A1. Figure 9 (a) shows deconvoluted mass spectrum of the intact antibody without deglycosylation (no time in the reactor chamber). Three main peaks were found. The mass difference between consecutive peaks is 163.9 and 161.8 amu, which corresponds to the characteristic mass difference, 162.05, of the terminal galactose on the G0, G1, and G2 glycans. Because A1 has two glycosylation sites, the peaks suggest a combination of G0, G1, and G2 glycans attached. Specifically, the masses indicate that A1 has the following glycan attachment configurations: G0 and G0, G0 and G1, G1 and G1, or G0 and G2.

Figure 9 (b) shows the partially deglycosylated antibody following a 3-s deglycosylation in the reactor chamber. Partially and completely deglycosylated A1 was measured. The peaks represent the partially deglycosylated forms as follows: 147,645.93 amu is from the A1 G0 form; 147,806.94 amu is the A1 G1 form; 146,201.21 amu is the deglycosylated form. The peak measuring 149,089.41 amu is intact A1 with two G0 glycans. The high mass accuracy of the TOF-MS enables detection of glycans differing by only one sugar monomer on very high molecular weight antibodies. Figure 9 (c) shows the deglycosylated antibody peak after 6-s residence time in the reactor chamber. Nearly all of the antibody was deglycosylated. The data indicated that this second chip configuration can be used to rapidly analyze deglycosylated antibody without the need for time-consuming sample preparation, deglycosylation, and separation steps.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here